Cellectar Biosciences (CLRB) announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology. In his most recent role as senior vice president hematology at TG Therapeutics (TGTX), he oversaw the sales, marketing and analytics teams for the hematology franchise.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLRB:
- Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
- Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference
- Society for Immunotherapy of Cancer to hold a meeting
- Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
- Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules